Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, announces that it has dosed the first patients in its Phase I/II clinical study of CAM-H2 for
Treatment with ruxolitinib cream (Opzelura) resulted in facial repigmentation at Week 24, characterized by a significant proportion of patients achieving =75% improvement from baseline in the facial
Decision taken to move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data Oxurion is moving into Part B of study evaluating THR-149
On 16 September 2021, the Court of Arbitration for Sport (CAS) handed down its Award in CAS 2021/A/7579 & 7580, dismissing the appeals of the World Anti-Doping Agency (WADA) and Sport Integrity Austr
- Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 - - Data support the use of toripalimab with chemotherapy as first-line therapy for